Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefan H Hohnloser

Showing results (1-10 of 335) with videos related to

Pageof 34
Sort By:
Nature Clinical Practice. Cardiovascular Medicine|August 26, 2006
Can microvolt T-wave alternans predict mortality in patients with ischemic cardiomyopathy?Stefan H Hohnloser
Journal of the American College of Cardiology|November 30, 2010
Stroke prevention versus bleeding risk in atrial fibrillation: a clinical dilemmaStefan H Hohnloser
European Heart Journal|September 4, 2014
Apixaban: a new direct oral anticoagulant for stroke prevention in atrial fibrillationStefan H Hohnloser
Heart Rhythm|May 3, 2008
T-wave alternans: a pathophysiological link to human ventricular tachyarrhythmiasStefan H Hohnloser
Journal of Cardiovascular Electrophysiology|May 16, 2008
Risk stratification using T-wave alternans: more questions waiting to be answeredStefan H Hohnloser
Cardiology Clinics|June 10, 2008
Risk factor assessment: defining populations and individuals at riskStefan H Hohnloser
Revista Espanola De Cardiologia|May 2, 2009
New pharmacological options for patients with atrial fibrillation: the ATHENA trialStefan H Hohnloser
Clinical Cardiology|January 17, 2012
Benefit-risk assessment of current antiarrhythmic drug therapy of atrial fibrillationStefan H Hohnloser
Journal of the American College of Cardiology|April 15, 2014
Dronedarone: "real-world" data vis-à-vis data from randomized clinical trialsStefan H Hohnloser
Journal of Cardiovascular Pharmacology and Therapeutics|June 21, 2005
Ventricular arrhythmias: antiadrenergic therapy for the patient with coronary artery diseaseStefan H Hohnloser
Pageof 34

Showing results (1-10 of 335) with videos related to

Sort By:
Pageof 34
Nature Clinical Practice. Cardiovascular Medicine|August 26, 2006
Can microvolt T-wave alternans predict mortality in patients with ischemic cardiomyopathy?Stefan H Hohnloser
Journal of the American College of Cardiology|November 30, 2010
Stroke prevention versus bleeding risk in atrial fibrillation: a clinical dilemmaStefan H Hohnloser
European Heart Journal|September 4, 2014
Apixaban: a new direct oral anticoagulant for stroke prevention in atrial fibrillationStefan H Hohnloser
Heart Rhythm|May 3, 2008
T-wave alternans: a pathophysiological link to human ventricular tachyarrhythmiasStefan H Hohnloser
Journal of Cardiovascular Electrophysiology|May 16, 2008
Risk stratification using T-wave alternans: more questions waiting to be answeredStefan H Hohnloser
Cardiology Clinics|June 10, 2008
Risk factor assessment: defining populations and individuals at riskStefan H Hohnloser
Revista Espanola De Cardiologia|May 2, 2009
New pharmacological options for patients with atrial fibrillation: the ATHENA trialStefan H Hohnloser
Clinical Cardiology|January 17, 2012
Benefit-risk assessment of current antiarrhythmic drug therapy of atrial fibrillationStefan H Hohnloser
Journal of the American College of Cardiology|April 15, 2014
Dronedarone: "real-world" data vis-à-vis data from randomized clinical trialsStefan H Hohnloser
Journal of Cardiovascular Pharmacology and Therapeutics|June 21, 2005
Ventricular arrhythmias: antiadrenergic therapy for the patient with coronary artery diseaseStefan H Hohnloser
Pageof 34